Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 28c
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
EPS Growth %: -30.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
SFNC, CSBR, MAN, More
EPS Growth %: -30.9%
Financial Fact:
Total operating costs and expenses: 3.91M
Today's EPS Names:
SFNC, CSBR, MAN, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.53, $0.28 better than the analyst estimate of $0.25. Revenue for the quarter came in at $99.5 million versus the consensus estimate of $92.73 million.
GUIDANCE:
Catalyst Pharmaceuticals sees Q3 2023 revenue of $380-390 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott (ABT) Tops Q2 EPS by 3c; offers guidance
- UnitedHealth Group (UNH) Tops Q2 EPS by $1.53, Beats on Revenue; Offers FY26 EPS Guidance
- Tanzanian Royalty Exploration (TRX) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
